The Maestro microelectrode array (MEA) platform is the state-of-the-art in MEA technology. Designed to be easily accessible yet powerful, the Maestro opens new avenues to interrogate cellular function. The Maestro combines real-time, noninvasive electrical measurements with full benchtop environmental control and a multi-well format to measure cellular networks in their native state.
- Flexible throughput in plate formats up to 96 wells accommodates all throughput needs on a single platform
- Easy-to-use hardware and software makes acquiring functional electrophysiological data accessible to everyone – no advanced training required
- Multiwell format facilitates collection of electrophysiological data at throughputs much higher than traditional patch clamp
- Label-free, non-invasive detection keeps cells healthy and intact during recording allowing the same population of cells to be monitored over hours, days, weeks or months.
- Industry-leading electrode count provides 8 or more recording sites in every well for built-in replicates and comprehensive population-based measurements
- On-board environmental control (temperature, CO₂ and humidity) ensures optimal cell health during benchtop recording
- Small footprint means you don’t have to give up valuable bench space for powerful data
Through thoughtful innovation, functional activity assays are now faster and easier to perform than ever.
Examine activity as a culture develops or collect data hours, days, weeks, and even months after a treatment. The label-free, non-invasive nature of MEAs means the same cells may be recorded repeatedly, adding flexibility and an extra dimension to experimental designs.
Learn about bench-top CO₂ control with the ECmini
The Maestro features:
- Industry-leading 768 recording channels
- Temperature, CO2 and humidity control
- Easy to use acquisition and analysis software (AxIS)
- Interchangeable 12-, 48-, or 96-well MEA plates
- Information-rich data collection rate (12.5 kHz)
- Built-in electrical stimulation
- Local technical support and training
The Maestro’s industry-leading 768 electrodes means more recording sites per well. More recording sites means more cells tested and a better representation of the population as a whole. It also means the ability to provide a high number of wells with enough electrodes per well to obtain meaningful data. With 12-, 48-, and an industry-leading 96-well format, the Maestro has an MEA plate with a combination of electrodes and wells suitable for all applications.
|Plate Format||Electrodes Per Well|
Axion never stops innovating. We continue to build on the value of the Maestro product by providing companion devices that expand its capabilities. Streamline your MEA experimental workflow with the Maestro APEX, the first-of-its-kind robotic interface that automates plate preparation, cell culture and MEA analysis. Pairing the Maestro with Lumos, a high-throughput optogenetic stimulation device, provides simultaneous optical control of cellular behavior during network activity recordings.
At the center, AxIS software provides a user-friendly experimental interface for assay creation and analysis.
|Document type||Title||Authors||Requires sign in|
|Application Document||Cardiac safety assessment human Pluricyte® Cardiomyocytes Maestro™ MEA system||Axion BioSystems, Pluriomics|
|Culture Protocol||CDI iCell® DopaNeurons Application Protocol||CDI|
|Application Document||AccuSpot Classic MEA 48 - Product flyer||Axion BioSystems, CDI|
|Culture Protocol||QBM Cell Science - Neonatal (P1) Rat DRG Neurons||Axion BioSystems|
|Application Document||CiPA - Application Note||Axion BioSystems|
|Culture Protocol||QBM Cell Science - E14,15 Embryonic C57 Mouse Cortical Neurons||Axion BioSystems|
|Application Document||CytoView MEA 48 - Product flyer||Axion BioSystems|
|Culture Protocol||QBM Cell Science - E18 Embryonic Rat Cortical Neurons||Axion BioSystems|
|Application Document||E-Stim+ Classic MEA 48 - Product flyer||Axion BioSystems, Pluriomics|
|Culture Protocol||Modeling Pain with Rat Dorsal Root Ganglion Neurons on MEAs||Axion BioSystems|
- 1 of 5
- next ›
||Developmental neurotoxicants disrupt activity in cortical networks on microelectrode arrays: Results of screening 86 compounds during neural network formation||Frank CL, Brown JP, Wallace K, Mundy WR, Shafer TJ.||Toxicol Sci||Aug 2017|
||Screening the ToxCast phase II libraries for alterations in network function using cortical neurons grown on multi-well microelectrode array (mwMEA) plates||Strickland JD, Martin MT, Richard AM, Houck KA, Shafer TJ.||Arch Toxicol||Aug 2017|
||Using induced pluripotent stem cells derived neurons to model brain diseases||McKinney CE.||Neural Regeneration Research||Aug 2017|
||A multivariate extension of mutual information for growing neural networks||Ball KR, Grant C, Mundy WR, Shafer TJ.||Neural Networks||Jul 2017|
||Developing hiPSC derived serum free embryoid bodies for the interrogation of 3-D stem cell cultures using physiologically relevant assays||Phillips AW, Nestor JE, Nestor MW.||Jove||Jul 2017|
||Application of stem cell derived neuronal cells to evaluate neurotoxic chemotherapy||Wing C, Komatsu M, Delaney SM, Krause M, Wheeler HE, Dolan ME.||Stem Cell Res||Jul 2017|
||Modeling psychomotor retardation using iPSCs from MCT8-deficient patients indicates a prominent role for the blood-brain barrier||Vatine GD, Al-Ahmad A, Barriga BK, Svendsen S, Salim A, Garcia L, Garcia VJ, Ho R, Yucer N, Qian T, Lim RG, Wu J, Thompson LM, Spivia WR, Chen Z, Van Eyk J, Palecek SP, Refetoff S, Shusta EV, Svendsen CN.||Cell Stem Cell||Jun 2017|
||Cryopreservation maintains functionality of human iPSC dopamine neurons and rescues Parkinsonian phenotypes in vivo||Wakeman DR, Hiller BM, Marmion DJ, McMahon CW, Corbett GT, Mangan KP, Ma J, Little LE, Xie Z, Perez-Rosello T, Guzman JN, Surmeier DJ, Kordower JH.||Stem Cell Reports||May 2017|
||Assaying spontaneous network activity and cellular viability using multi-well microelectrode arrays||Brown JP, Lynch BS, Curry-Chisolm IM, Shafer TJ, Strickland JD.||Methods Mol Biol||May 2017|
||Neuropharmacological characterization of the new psychoactive substance methoxetamine||Hondebrink L, Kasteel EEJ, Tukker AM, Wijnolts FMJ, Verboven AHA, Westerink RHS.||Neuropharmacology||Apr 2017|
- 1 of 7
- next ›
- 1 of 5
- next ›